Align Technology filings document the regulatory record for a medical device company built around Invisalign clear aligners, iTero intraoral scanners, exocad CAD/CAM software and digital dentistry workflows. Its 8-K filings report operating and financial results, capital-structure actions, material events and governance changes, including bylaw amendments and executive compensation-related matters.
Proxy materials describe board structure, independence, risk oversight, shareholder voting items, executive compensation and governance policies. The filing record also captures shareholder meeting matters, stockholder rights provisions, common-stock disclosures and risk topics tied to Align's global clear-aligner, imaging systems and CAD/CAM services businesses.
ALIGN TECHNOLOGY INC (symbol: ALGN) is the issuer of record for a Form 4 filing submitted to the SEC.
ALIGN TECHNOLOGY INC (ALGN) filed an initial statement of beneficial ownership (Form 3) for Quentin S. Blackford, who is identified as a director of the company. The filing does not report any equity transactions or initial holdings, and includes an exhibit for a limited power of attorney.
Align Technology, Inc. (ALGN) announced that its Board of Directors appointed Quentin Blackford, President and CEO of iRhythm Technologies, as a director effective August 27, 2026, increasing the Board size from ten to eleven directors. He is expected to stand for election at the May 2027 annual meeting and will receive prorated non-employee director compensation under Align’s existing program, along with a standard director indemnification agreement.
Andrea L. Saia notified the Board that she will retire as a director effective September 23, 2026; her decision is stated not to result from any disagreement with Align on operations, policies or practices. Upon her resignation, the Board size will automatically decrease back to ten directors. Align highlights its scale with over 302.0 thousand doctor customers and approximately 23.5 million Invisalign patients treated within a 600 million consumer market opportunity.
Capital World Investors, a division of Capital Research and Management Company and related investment management entities, reported beneficial ownership of 3,571,496 shares of Align Technology, Inc. common stock. This represents 5.0% of the 71,618,127 shares believed to be outstanding as of the reporting date.
Capital World Investors reported sole voting power over 3,550,442 shares and sole dispositive power over 3,571,496 shares, with no shared voting or dispositive power. The filing reflects the status of a significant institutional holder of Align Technology’s common stock.
Align Technology, Inc. is reported to have 5.4% of its Common Stock beneficially owned by a group of related trusts and individuals led by members of the Gund family. The group reports beneficial ownership of 3,812,981 shares based on 71,039,852 shares outstanding as of July 31, 2026.
Within the group, G. Zachary Gund may be deemed to own 1,875,147 shares (2.6% of the class) and Grant Gund 1,435,981 shares (2.0%), mainly through multiple trusts and LLCs where they act as trustee, manager, or co‑manager. Several additional trusts and the Gordon & Llura Gund Foundation each report smaller fractional percentages, with varying sole or shared voting and dispositive powers.
FMR LLC filed as a significant holder of Align Technology common stock, reporting 4,060,032.23 shares beneficially owned as of June 30, 2026. This position represents 5.7% of the outstanding common stock.
FMR LLC reports sole dispositive power over 4,060,032.23 shares and sole voting power over 4,008,802.08 shares, with no shared voting or dispositive power. Abigail P. Johnson is also listed as a reporting person with sole dispositive power over the same 4,060,032.23 shares, but no voting power. One or more other persons may receive dividends or sale proceeds from these shares, but no such person has more than 5% of the class.
Align Technology reported net revenues of $1,056.2 million for the quarter ended June 30 2026, up 4.3% year over year. Clear Aligner revenues rose to $870.9 million, while Systems and Services declined to $185.3 million. Income from operations was $154.0 million, an operating margin of 14.6%, and net income was $108.3 million, or $1.51 per diluted share. The effective tax rate was 27.2%.
For the first six months of 2026, net revenues reached $2,096.3 million and net income $221.1 million. Operating cash flow was $343.8 million, with cash and cash equivalents of $1,102.6 million at June 30 2026. The company invested in growth and capacity, including capital expenditures and a planned $200 million manufacturing facility in Hyderabad, India expected to start operations in 2027, while repurchasing about 0.4 million shares for $66.7 million. Results were affected by $69.3 million in legal settlements and contingencies for the first half, accelerated depreciation of $15.6 million tied to prior restructuring, and an accrued $37.5 million UK VAT liability following an adverse tribunal decision, even as the company recorded favorable outcomes in certain patent and antitrust litigations.
Align Technology, Inc. announced a set of governance, strategic, and capital-allocation initiatives intended to support long-term growth and shareholder value. Following discussions with Elliott Investment Management, the company plans to appoint three new independent directors to its Board, focusing on candidates with healthcare, medical device, technology, and global operations experience.
Align has begun a comprehensive strategic and operating model review with a global consulting firm, aimed at strengthening commercial execution, organizational effectiveness, resource optimization, and scalability, with the goal of supporting sustainable revenue growth and margin expansion. The company increased its 2026 share repurchase commitment and now intends to repurchase $400 million to $500 million of common stock during 2026. Align reports over 302.0 thousand doctor customers, a 600 million consumer market opportunity, and approximately 23.5 million patients treated with Invisalign over 29 years.
Align Technology reported record Q2 2026 revenue of $1,056.2 million, up 4.3% year-over-year and 1.5% sequentially. Clear Aligner revenue was $870.9 million, up 8.2% year-over-year on record shipments of 691.8 thousand cases, while Imaging Systems and CAD/CAM Services revenue was $185.3 million, down 10.8% year-over-year.
GAAP gross margin was 71.7% and operating margin 14.6%; on a non-GAAP basis, gross margin was 72.3% and operating margin 22.9%. GAAP net income was $108.3 million, or $1.51 per diluted share, and non-GAAP diluted EPS was $2.64. Cash and cash equivalents were $1,102.6 million, with six‑month operating cash flow of $343.8 million. The company repurchased about 393.4 thousand shares for approximately $67 million and plans total 2026 repurchases of $400–$500 million. Align recorded an estimated $37.5 million UK VAT liability and will begin charging 20% UK VAT on applicable products from September 7, 2026. Management expects Q3 2026 revenue of $1.00–$1.02 billion and continues to target 3–4% full‑year 2026 revenue growth with higher GAAP and non-GAAP operating margins versus 2025.
Align Technology, Inc. reported that Julie Coletti, its Executive Vice President and Chief Legal and Regulatory Officer, has resigned to join Illumina, Inc. as Chief Legal Officer. The company states that her resignation was submitted on July 6, 2026 and will be effective August 1, 2026.
The filing does not describe any dispute or disagreement, indicating the change is related to Ms. Coletti’s decision to take a new role at another company.